Role of Buprenorphine in Improving Clinical Care in Opioid Addiction and HIV

丁丙诺啡在改善阿片类药物成瘾和艾滋病毒临床护理中的作用

• 批准号: 7546806
• 负责人: Elinore F. McCance-Katz
• 金额: $ 18.17万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-15 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7546806
• 关键词: Agonist; Anesthesiology; Anti-Retroviral Agents; Area; Atazanavir; Award; Buprenorphine; Caring; Clinical; Clinical Investigator; Clinical Pharmacology; Clinical Research; Clinical Trials; Clinical Trials Network; Combination Medication; Data Analyses; Development; Didanosine; Disease; Drug Interactions; Drug user; Educational Activities; Faculty; Funding; Goals; Grant; HIV; Human; Human Subject Research; Individual; K-Series Research Career Programs; Laboratories; Lead; Maintenance; Manuscripts; Medical; Medical Students; Medicine; Mentors; Mentorship; Methadone; Methadyl Acetate; Midcareer Investigator Award in Patient-Oriented Research; Naloxone; National Institute of Drug Abuse; Nevirapine; Numbers; Opiate Addiction; Opiates; Opioid; Patients; Pediatrics; Pharmaceutical Preparations; Physicians; Physicians' Offices; Postdoctoral Fellow; Preparation; Psychiatry; Qualifying; Research; Research Design; Research Methodology; Research Personnel; Research Project Grants; Research Proposals; Research Training; Ritonavir; Role; Students; Tenofovir; Therapeutic; Time; Toxic effect; Training; addiction; antiretroviral therapy; base; career; fosamprenavir; improved; interest; medical schools; patient oriented research; prescription document; prescription procedure; success

DESCRIPTION (provided by applicant): This Midcareer Investigator Award in Patient Oriented Research (K24) will provide the candidate with the opportunity to continue her own career development, to continue to mentor beginning clinical investigators, resident physicians, and students in research methods, to disseminate new research findings in addiction medicine, specifically in the treatment of opioid dependence and comorbid opioid dependence and HIV disease, and to continue research in defining drug interactions between buprenorphine and antiretroviral medications as well as to undertake clinical trials to further illuminate how to effectively treat prescription opioid addiction. The overarching goal of this K award will be to enhance the clinical care of opioid-addicted patients through the successful completion of currently funded NIDA studies and to use the clinical research setting to train young investigators in addiction medicine and in the undertaking of well-designed research that will ultimately lead to their success as independent investigators. The Specific Aims of the research proposal include completion of the Pi's funded NIDA RO1 research project to identify drug interactions and their clinical importance between buprenorphine, a newer opioid partial agonist available by prescription from qualified physicians and HIV therapeutics and a clinical trial funded through the NIDA Clinical Trials Network that will examine buprenorphine/naloxone treatment plus medical management or enhanced medical management for treatment of patients addicted to prescription opioids. The mentoring plan will focus on training junior faculty in psychiatry, medicine, anesthesiology, and pediatrics, psychiatry residents, postdoctoral fellows in addiction psychiatry, medical students, and graduate and undergraduate students to conduct patient-oriented research in addiction medicine. The training will focus on clinical research methods including human laboratory-based paradigms and clinical trials, data analysis, manuscript and grant preparation, presentation of research findings, conduct of ethical research and human subjects protections. Mentoring will occur through participation in the Pi's funded research projects and educational activities available within Addiction Psychiatry, the School of Medicine, and VCU. Over the next 5 years the candidate seeks to devote full time effort to research and mentoring with the goal of advancing patient oriented research in opioid dependence and helping to increase the number of new investigators in the field.

描述（由申请人提供）：这项面向患者的研究（K24）职业中期研究者奖将为候选人提供机会，继续她自己的职业发展，继续指导初级临床研究者，住院医生和学生的研究方法，传播成瘾医学的新研究成果，特别是在治疗阿片类药物依赖和合并症阿片类药物依赖和艾滋病毒疾病方面。并继续研究丁丙诺啡和抗逆转录病毒药物之间的药物相互作用，并进行临床试验，以进一步阐明如何有效治疗处方阿片类药物成瘾。这个K奖的总体目标是通过成功完成目前资助的NIDA研究来加强阿片类药物成瘾患者的临床护理，并利用临床研究环境来培训成瘾医学方面的年轻研究人员，并进行精心设计的研究，最终使他们成为成功的独立研究人员。该研究计划的具体目标包括完成Pi资助的NIDA RO1研究项目，以确定丁丙诺啡和丁丙诺啡之间的药物相互作用及其临床重要性。一种新的阿片类药物部分激动剂，可通过合格医生的处方获得；艾滋病毒疗法；一项由NIDA临床试验网络资助的临床试验，该试验将检查丁丙诺啡/纳洛酮治疗加医疗管理或加强医疗管理，以治疗处方阿片类药物成瘾的患者。该指导计划将重点培训精神病学、医学、麻醉学和儿科的初级教师、精神病学住院医师、成瘾精神病学博士后、医学院学生、研究生和本科生，以开展成瘾医学方面以患者为导向的研究。培训将侧重于临床研究方法，包括基于人类实验室的范例和临床试验、数据分析、手稿和拨款准备、研究成果的介绍、伦理研究的开展和人类受试者的保护。指导将通过参与Pi资助的研究项目和成瘾精神病学，医学院和VCU提供的教育活动来实现。在接下来的5年里，候选人寻求将全职工作投入到研究和指导中，以推进阿片类药物依赖的面向患者的研究，并帮助增加该领域新研究人员的数量。